A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles-Reference-Cited by-同舟云学术

A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles

Published:2004-04 Issue:4 Volume:69 Page:271-278
ISSN:0010-7824
Container-title:Contraception
language:en
Short-container-title:Contraception

Author:

Gaspard U.,Endrikat J.,Desager J.P.,Buicu C.,Gerlinger C.,Heithecker R.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Reproductive Medicine

Reference31 articles.

1. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for proprietary medicinal products (CPMP). Note for guidance on clinical investigation of steroid contraceptives in women. 17 February 2000 CPMP/EWP/519/98

2. Safety of modern oral contraceptives;Crook;Contraception,1998

3. The effect of progestins on plasma lipids;Tikkanen,2000

4. HDL and arteriosclerosis;Nofer;Atherosclerosis,2002

5. The rationale for a wider range of progestogens;Skouby;Climacteric,2000

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of combined oral contraceptive on cardiorespiratory function and immune activation in premenopausal women involved in exercise: A systematic review protocol;PLOS ONE;2024-02-23

2. Subdermal Progestin Implant and an Oral Combined Hormonal Contraceptive in Youth with Type 1 Diabetes;Journal of Pediatric and Adolescent Gynecology;2023-11

3. Association between oral contraceptives with lipid profile: results from Hoveyzeh cohort study (HCS);BMC Women's Health;2023-10-24

4. Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen;Women's Health;2023-01

5. Control of side effects in strategy for increasing adherence to combined oral contraceptives. The role for a three-phase desogestrel-containing drug;Obstetrics, Gynecology and Reproduction;2022-06-27